Abstract

Many microbial pathogens subvert cell surface heparan sulfate proteoglycans (HSPGs) to infect host cells in vitro. The significance of HSPG-pathogen interactions in vivo, however, remains to be determined. In this study, we examined the role of syndecan-1, a major cell surface HSPG of epithelial cells, in Staphylococcus aureus corneal infection. We found that syndecan-1 null (Sdc1(-/-)) mice significantly resist S. aureus corneal infection compared with wild type (WT) mice that express abundant syndecan-1 in their corneal epithelium. However, syndecan-1 did not bind to S. aureus, and syndecan-1 was not required for the colonization of cultured corneal epithelial cells by S. aureus, suggesting that syndecan-1 does not mediate S. aureus attachment to corneal tissues in vivo. Instead, S. aureus induced the shedding of syndecan-1 ectodomains from the surface of corneal epithelial cells. Topical administration of purified syndecan-1 ectodomains or heparan sulfate (HS) significantly increased, whereas inhibition of syndecan-1 shedding significantly decreased the bacterial burden in corneal tissues. Furthermore, depletion of neutrophils in the resistant Sdc1(-/-) mice increased the corneal bacterial burden to that of the susceptible WT mice, suggesting that syndecan-1 moderates neutrophils to promote infection. We found that syndecan-1 does not affect the infiltration of neutrophils into the infected cornea but that purified syndecan-1 ectodomain and HS significantly inhibit neutrophil-mediated killing of S. aureus. These data suggest a previously unknown bacterial subversion mechanism where S. aureus exploits the capacity of syndecan-1 ectodomains to inhibit neutrophil-mediated bacterial killing mechanisms in an HS-dependent manner to promote its pathogenesis in the cornea.

Highlights

  • Eight-twenty-one (ETO; known as MTG8 [myeloid tumor gene 8] [8, 34]) was identified at the breakpoint of t(8;21), little is known about the normal function of the protein

  • Our transcriptional analysis of the t(8;21) fusion protein indicated that acute myeloid leukemia-1 (AML-1)/ETO repressed transcription by recruiting a corepressor

  • Analysis of the transcriptional regulatory activity of the t(8; 21) fusion protein led us to propose that AML-1/ETO interacts with a corepressor [24, 32]

Read more

Summary

Introduction

Eight-twenty-one (ETO; known as MTG8 [myeloid tumor gene 8] [8, 34]) was identified at the breakpoint of t(8;21), little is known about the normal function of the protein. AML-1 is a site-specific DNA binding protein that can both activate and repress transcription [2, 28, 36]. The t(8;21) fusion protein AML-1/ETO contains the N-terminal 177 amino acids of AML-1, including the DNA binding domain, fused to most of ETO [7, 8, 34]. AML-1/ETO-mediated repression is dependent on both the DNA binding domain of AML-1 and ETO sequences [24]. N-CoR and the related protein SMRT are released from nuclear hormone receptors upon ligand binding, allowing transcriptional activation [5, 16, 22, 35]. Single amino acid substitutions in the MYND domain that affect the ability of ETO to interact with the central portion of N-CoR impair AML-1/ ETO-mediated repression of the NP-3 promoter. T(8;21) fuses the DNA binding domain of AML-1 to a putative corepressor, ETO

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call